Findings

What do systematic reviews say?

4,411 questions · 5,986 findings · 226 reviews · Oral Health

Sort:Best matchNewestHighest certainty Download CSV

No studies found 1,305 · 21.8%GRADE not reported 2,988 · 49.9%Very low 1,030 · 17.2%Low 476 · 8%Moderate 156 · 2.6%High 31 · 0.5%

Ranked among the 5,000 newest matching findings; add words or filters to narrow the search.

GM-CSF vs placebo or no treatment

Normalcy of diet (total parenteral nutrition) · Adults with cancer receiving treatment

Granulocyte-macrophage colony-stimulating factor (GM-CSF) showed no clear difference in normalcy of diet (total parenteral nutrition) compared with placebo or no treatment; GRADE not reported.

1 finding from 1 review

Interventions for preventing oral mucositis in patients with cancer receiving treatment: cytokines and growth factors 2017 · Cochrane All outcomes
BMT/SCT after conditioning for haematological cancers
RR 1.10 [0.63, 1.91]
1 study · 36 participants
GRADE not reported

Antimicrobial lozenge vs placebo

Nausea · Patients receiving radiotherapy on its own or in addition to chemotherapy to the head and neck region

Antimicrobial lozenge led to higher nausea (adverse effect) compared with placebo; GRADE not reported.

1 finding from 1 review

Pharmacological interventions for preventing dry mouth and salivary gland dysfunction following radiotherapy 2017 · Cochrane All outcomes
Over 6 months
RR 1.90 [1.10, 3.28]
1 study · 131 participants
GRADE not reported

Antiseptic mouthrinse vs placebo

Survival · Patients receiving radiotherapy on its own or in addition to chemotherapy to the head and neck region

The review found no eligible studies for this question.

1 finding from 1 review

Pharmacological interventions for preventing dry mouth and salivary gland dysfunction following radiotherapy 2017 · Cochrane All outcomes
No survival data were reported.
0 studies
No studies found

Periodontal treatment (scaling and root planing, polishing, or surgery), alone or with oral hygiene counselling, antiseptics, or antimicrobials vs no treatment

Attachment change · Pregnant women considered to have periodontal disease (gingivitis or periodontitis) after dental examination

1 finding from 1 review

Treating periodontal disease for preventing adverse birth outcomes in pregnant women 2017 · Cochrane All outcomes
Reported as a secondary periodontal outcome (Analysis 1.7); results not meta-analysed due to considerable heterogeneity (I2 91% to 100%); reduction in favour of periodontal treatment.
4 studies
GRADE not reported

Amifostine 200 mg/m2 three times weekly vs Amifostine 200 mg/m2 five times weekly

Salivary flow rate · Patients receiving radiotherapy on its own or in addition to chemotherapy to the head and neck region

The review found no eligible studies for this question.

1 finding from 1 review

Pharmacological interventions for preventing dry mouth and salivary gland dysfunction following radiotherapy 2017 · Cochrane All outcomes
No salivary flow rate data related to the effectiveness of different doses of amifostine were reported.
0 studies
No studies found

Keratinocyte growth factor (KGF; palifermin or repifermin), intravenous vs Chlorhexidine mouthwash

Oral mucositis (severe) · Children with acute lymphoblastic leukaemia receiving chemotherapy alone

Keratinocyte growth factor (KGF), intravenous led to lower oral mucositis (severe) compared with chlorhexidine mouthwash; GRADE not reported.

1 finding from 1 review

Interventions for preventing oral mucositis in patients with cancer receiving treatment: cytokines and growth factors 2017 · Cochrane All outcomes
Children
RR 0.01 [0.00, 0.19]
1 study · 90 participants
GRADE not reported

Pilocarpine vs no treatment/placebo

Adverse effects (other reported events) · Patients receiving radiotherapy on its own or in addition to chemotherapy to the head and neck region

1 finding from 1 review

Pharmacological interventions for preventing dry mouth and salivary gland dysfunction following radiotherapy 2017 · Cochrane All outcomes
No evidence of a difference for any other adverse event (nausea, vomiting, chilling, headache, lacrimation, dysphasia, weakness, nervousness, rhinitis, blurred vision, urinary frequency, dizziness, palpitation, skin…
Studies not reported
GRADE not reported

Resorbable (bioresorbable) plates or screws for fixation vs Titanium plates or screws for fixation

Swelling (mean) · Adults (>16 years old) undergoing orthognathic surgery

1 finding from 1 review

Resorbable versus titanium plates for orthognathic surgery 2017 · Cochrane All outcomes
Up to 3 years postoperatively
Though Cheung 2004 reported the presence of postoperative swelling, it was only noted in conjunction with infection and pus discharge; assessment of this outcome did not include the use of photography or digital…
1 study · 60 participants
GRADE not reported

Amifostine 200 mg/m2 three times weekly vs Amifostine 200 mg/m2 five times weekly

Nausea · Patients receiving radiotherapy on its own or in addition to chemotherapy to the head and neck region

Amifostine 200 mg/m2 three times weekly showed no clear difference in nausea (adverse effect) compared with amifostine 200 mg/m2 five times weekly; GRADE not reported.

1 finding from 1 review

Pharmacological interventions for preventing dry mouth and salivary gland dysfunction following radiotherapy 2017 · Cochrane All outcomes
RR 0.64 [0.33, 1.25]
1 study · 60 participants
GRADE not reported

GM-CSF vs placebo or no treatment

Number of days of treatment with opioid analgesics · Adults with cancer receiving treatment

Granulocyte-macrophage colony-stimulating factor (GM-CSF) led to lower number of days of treatment with opioid analgesics compared with placebo or no treatment; GRADE not reported.

1 finding from 1 review

Interventions for preventing oral mucositis in patients with cancer receiving treatment: cytokines and growth factors 2017 · Cochrane All outcomes
BMT/SCT after conditioning for haematological cancers
MD -1.10 [-1.91, -0.29]
1 study · 90 participants
GRADE not reported

Amifostine 200 mg/m2 three times weekly vs Amifostine 200 mg/m2 five times weekly

Xerostomia (grade >= 2, 0-4 scale) · Patients receiving radiotherapy on its own or in addition to chemotherapy to the head and neck region

Amifostine 200 mg/m2 three times weekly showed no clear difference in xerostomia (grade >= 2, 0-4 scale) compared with amifostine 200 mg/m2 five times weekly; GRADE not reported.

1 finding from 1 review

Pharmacological interventions for preventing dry mouth and salivary gland dysfunction following radiotherapy 2017 · Cochrane All outcomes
12 months postRT
RR 0.94 [0.58, 1.53]
1 study · 49 participants
GRADE not reported

ART using glass ionomer cement (GIC) vs Amalgam restoration

Pain (permanent, immature teeth) · Children and adolescents with dental caries (primary teeth and permanent immature teeth)

ART using glass ionomer cement (GIC) led to lower pain (permanent, immature teeth) compared with conventional treatment using amalgam; GRADE not reported.

1 finding from 1 review

Atraumatic restorative treatment versus conventional restorative treatment for managing dental caries 2017 · Cochrane All outcomes
OR 0.41 [0.35, 0.47]
1 study
GRADE not reported

Venalot Depot (coumarin plus troxerutin) vs placebo

Side effects · Patients receiving radiotherapy on its own or in addition to chemotherapy to the head and neck region

1 finding from 1 review

Pharmacological interventions for preventing dry mouth and salivary gland dysfunction following radiotherapy 2017 · Cochrane All outcomes
No adverse events could be attributed to the experimental medication (Grotz 2001)
1 study
GRADE not reported

ART using resin-modified glass ionomer cement (RM-GIC) vs Conventional treatment using RM-GIC

Restoration failure (primary dentition) · Older adults with root caries in permanent (mature) teeth (mean age 75 years)

The review found no eligible studies for this question.

1 finding from 1 review

Atraumatic restorative treatment versus conventional restorative treatment for managing dental caries 2017 · Cochrane All outcomes
Restoration failure (primary dentition): 0 studies; No studies included.
0 studies
No studies found

Zinc vs placebo

Taste acuity improvement - objective outcome (dichotomous) - chronic renal failure · Patients with taste disturbances (dysgeusia/hypogeusia; idiopathic, zinc-deficient, or secondary to chronic renal failure)

Zinc supplements (zinc sulphate, zinc gluconate, zinc picolinate,… led to higher taste acuity improvement - objective outcome (dichotomous) - chronic… compared with placebo; GRADE not reported.

1 finding from 1 review

Interventions for managing taste disturbances 2017 · Cochrane All outcomes
Chronic renal failure
RR 25 [1.65, 379.57]
1 study · 24 participants
GRADE not reported

Metal-free FDPs (zirconia ceramic) vs Metal-ceramic FDPs

Bridge complications · Adults (18 years or older) needing a three-unit fixed dental prosthesis (FDP)

It is very uncertain whether metal-free FDPs (zirconia ceramic) changes bridge complications compared with metal-ceramic FDPs (very low certainty).

1 finding from 1 review

Metal‐free materials for fixed prosthodontic restorations 2017 · Cochrane All outcomes
36 months
OR 1.94 [0.38, 9.88]
1 study · 34 participants
Very low

Selenium vs no intervention

Side effects · Patients receiving radiotherapy on its own or in addition to chemotherapy to the head and neck region

1 finding from 1 review

Pharmacological interventions for preventing dry mouth and salivary gland dysfunction following radiotherapy 2017 · Cochrane All outcomes
6 weeks after end of RT
23 serious adverse events in the selenium group versus 22 in the control group (P = 0.476); no significant differences in toxicities (Buntzel 2010)
1 study
GRADE not reported

Keratinocyte growth factor (KGF; palifermin or repifermin), intravenous vs placebo

Mouth and throat soreness (OMWQ-HN, 0-4 scale) · Patients receiving radiotherapy on its own or in addition to chemotherapy to the head and neck region

Palifermin showed no clear difference in mouth and throat soreness (OMWQ-HN, 0-4 scale) compared with placebo; GRADE not reported.

1 finding from 1 review

Pharmacological interventions for preventing dry mouth and salivary gland dysfunction following radiotherapy 2017 · Cochrane All outcomes
3 months postRT
MD -0.12 [-0.27, 0.02]
2 studies
GRADE not reported

Intestinal trefoil factor (ITF), lower dose (336 mg) vs Intestinal trefoil factor (ITF), higher dose (2688 mg)

Oral mucositis (any severity) · Adults receiving chemotherapy alone for colorectal cancer

1 finding from 1 review

Interventions for preventing oral mucositis in patients with cancer receiving treatment: cytokines and growth factors 2017 · Cochrane All outcomes
Insufficient evidence to determine whether lower (336 mg) or higher (2688 mg) dose performs better (Analyses 11.1 to 11.3); no pooled estimate reported
1 study · 66 participants
GRADE not reported

Topical NSAID (ketoprofen chewing gum) vs Local anaesthetic (benzocaine chewing gum)

Adverse events · People undergoing orthodontic treatment (any age; 9 to 34 years in included studies)

The review found no eligible studies for this question.

1 finding from 1 review

Pharmacological interventions for pain relief during orthodontic treatment 2017 · Cochrane All outcomes
The study did not report this outcome.
0 studies
No studies found